Floatz logo

ect204 t cells

Liver Neoplasm

Eureka Therapeutics Inc.Cell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Liver Neoplasm cohort.

Asset / SponsorPhaseRating
Irinotecan
Tehran University of Medical Sciences
Phase 4BBB
Eloxatin
Shanghai Zhongshan Hospital
Phase 4BB
ALBUMIN AGGREGATED
Sirtex Medical
Phase 4BB
CHLORHEXIDINE
Changhua Christian Hospital
Phase 4BB
FLUOROURACILUM
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 4BB

View all 50 →

Same molecule, other indications

ect204 t cells is also rated in:

liver cancerDormant
CC
Indicative ·
47 / 100
View asset →
hepatocellular carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →